Department of Gynecology, Obstetrics and Neonatology, Policlinico di Bari, University of Bari, Bari, Italy.
Oncology. 2011;80(1-2):102-6. doi: 10.1159/000328794. Epub 2011 Jun 14.
The aim of this study was to evaluate our experience with patients affected by ovarian carcinosarcoma.
During a 16-year period, data on 13 patients with ovarian carcinosarcoma were collected. They were obtained from hospital charts and follow-up visits. Survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test. All tests were two-tailed with p values < 0.05 considered significant.
Our study was conducted on 13 patients with ovarian carcinosarcoma referred to our unit, during an observation time of about 16 years (March 1994 to October 2010). An improved survival was observed in patients treated with optimal cytoreductive surgery with residual tumors <2 cm (30 vs. 5 months; p = 0.042). All patients underwent adjuvant chemotherapy based on the combination of cisplatin, epirubicin and ifosfamide (PEI) and taxol and carboplatin (TAX-CBDCA) regimen. Overall survival of the patient population was 17 months.
Similarly to data published in the literature, we observed that malignant mixed mullerian ovarian tumors are very aggressive and are usually diagnosed at an advanced age and at an advanced stage of disease. Therefore, due to the rarity of the tumor we would like to add our series to those already published in the literature, although our treatment recommendations are actually based upon retrospective studies with a small patient population.
本研究旨在评估我们在卵巢癌肉瘤患者治疗方面的经验。
在 16 年期间,共收集了 13 例卵巢癌肉瘤患者的数据。这些数据来源于病历和随访。采用 Kaplan-Meier 方法估计生存曲线,并使用对数秩检验进行比较。所有检验均为双侧检验,p 值<0.05 认为具有统计学意义。
我们的研究共纳入了 13 例在我院就诊的卵巢癌肉瘤患者,观察时间约为 16 年(1994 年 3 月至 2010 年 10 月)。接受理想肿瘤细胞减灭术(残余肿瘤<2cm)的患者生存得到改善(30 个月与 5 个月;p=0.042)。所有患者均接受了以顺铂、表阿霉素和异环磷酰胺(PEI)联合紫杉醇和卡铂(TAX-CBDCA)方案为基础的辅助化疗。患者的总体生存率为 17 个月。
与文献中发表的数据类似,我们观察到恶性混合性苗勒管肿瘤非常具有侵袭性,通常在高龄和疾病晚期被诊断。因此,由于肿瘤的罕见性,我们希望将我们的系列研究添加到已经发表的文献中,尽管我们的治疗建议实际上是基于小样本量的回顾性研究。